This article is more than 5 years old. Information may no longer be current.

VIDEO: Cancer vaccine targets glioblastoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Michael Ciesielski, PhD, assistant professor in the department of neurosurgery at Roswell Park Comprehensive Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about SurVaxM.

The cancer vaccine is under investigation for patients with newly diagnosed glioblastoma

SurVaxM (MimiVax) targets survivin, a cell-survival protein present in 95% of glioblastomas.

In this video, Ciesielski discusses results of an interim analysis from that assessed survival outcomes among 63 patients treated with SurVaxM in a phase 2 trial.